Delivery Order SPE2DB22D9353-SPE2DB25FX1VH
Award Date
4/18/25
Potential Completion Date
5/9/25
Potential Value
$99K
Federal Agency
Defense Logistics Agency
Awardee
DMS Pharmaceutical Group Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $16,441.36, is for the delivery of 4,568,023,214 units of the biologic medication Stelara (90 mg/mL syringe). The award date is April 18, 2025, and the ultimate completion date is May 9, 2025. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $16,441.36 contract is for the delivery of STELARA 90 MG/ML SYRINGEML, a specialized pharmaceutical product, with a performance period ending on April 22, 2025. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract, valued at $16,441.36, is for the delivery of 4,568,151.64 milliliters of the prescription drug STELARA (90 mg/ml syringe). The contract has an ultimate completion date of May 8, 2025 and was awarded on April 17, 2025. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $8,220.68, is for the delivery of Stelara 90 mg/ml syringes. The contract has an ultimate completion date of April 28, 2025 and was awarded on April 7, 2025. DMS Pharmaceutical Group Inc. is the prime contractor, and there are no major subcontractors mentioned. This delivery order is part...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order worth $49,324.08 to DMS Pharmaceutical Group Inc., a woman-owned small business, for the supply of the pharmaceutical product STELARA 90 MG/ML SYRINGE. The delivery order has an ultimate completion date of April 29, 2025 and is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program. This IDC enables the DLA to issue delivery orders for...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the supply of the drug Stelara 90 mg/ml syringe. The award, valued at $7,108.82, has a period of performance through May 10, 2024. This delivery order is placed under a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group worth up to $499,999,999, which allows the DLA to issue firm fixed-price orders for a wide...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract has a ceiling value of $8,220.68 and is for the delivery of Stelara 90 mg/ml syringes. The contract is a firm fixed-price delivery order with a period of performance through March 5, 2025. DMS Pharmaceutical Group holds a larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $16,441.36 contract provides for the delivery of STELARA 90 MG/ML SYRINGEML, a specialized pharmaceutical product, to support the medical supply needs of military healthcare facilities. The contract has an ultimate completion date of April 30, 2025 and is not associated with a set-aside designation. DMS...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $8,220.68, is for the delivery of Stelara 90 mg/ml syringes to support the medical supply needs of military healthcare facilities. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the agency to...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $32,882.72, is for the supply of Stelara 90 mg/ml syringes. It is a firm fixed-price delivery order contract with an ultimate completion date of April 3, 2025. DMS Pharmaceutical Group Inc. holds a larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999...